How should I document a SOAP note with appropriate CPT and ICD‑10 codes for a 67‑year‑old male presenting for ER follow‑up of weeks‑long diarrhea, nausea, and abdominal pain, with CT abdomen/pelvis showing hepatic steatosis, hyperglycemia (glucose 298 mg/dL), past cholecystectomy, hypertension, uncontrolled type 2 diabetes on insulin, and a need for gastroenterology referral, repeat labs, and a Helicobacter pylori urea breath test?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

SOAP Note Documentation for ER Follow-Up: Chronic Diarrhea with Hepatic Steatosis and Uncontrolled Diabetes

For a 67-year-old male with weeks-long diarrhea following cholecystectomy, test for bile acid diarrhea (BAD) first, as post-cholecystectomy patients have an 86% likelihood of positive testing, making this the most probable diagnosis 1.


SUBJECTIVE

Chief Complaint: ER follow-up for chronic diarrhea, nausea, and abdominal pain

History of Present Illness:

  • Duration: Several weeks of symptoms causing work absences
  • Symptoms: Diarrhea (specify frequency, consistency, presence of blood), nausea, abdominal pain (document location—right upper quadrant given history)
  • ER findings: CT abdomen/pelvis showed hepatic steatosis; glucose 298 mg/dL
  • Past surgical history: Cholecystectomy (critical risk factor for bile acid diarrhea)

Past Medical History:

  • Hypertension
  • Type 2 diabetes mellitus, uncontrolled (on insulin)
  • Status post cholecystectomy

Current Medications:

  • Insulin (specify type and dose)
  • Antihypertensive (specify)
  • Note: Ozempic previously denied by insurance—resubmitting

Review of Systems:

  • Document weight changes, nocturnal diarrhea (suggests BAD or microscopic colitis), urgency, bloating
  • Screen for symptoms of hypoglycemia given uncontrolled diabetes 2

OBJECTIVE

Vital Signs: BP, HR, weight (compare to previous), BMI

Physical Examination:

  • General: Assess hydration status, nutritional state
  • Abdomen: Tenderness (especially RUQ), hepatomegaly, surgical scars
  • Skin: Assess for signs of chronic liver disease, insulin injection sites

Laboratory Data (from ER):

  • Glucose: 298 mg/dL (significantly elevated)
  • CT abdomen/pelvis: Hepatic steatosis (no mention of cirrhosis, masses, or other pathology)

ASSESSMENT

  1. Chronic diarrhea, likely bile acid diarrhea (BAD) secondary to cholecystectomy (ICD-10: K91.1 - Postcholecystectomy syndrome)

    • Post-cholecystectomy patients have 86% likelihood of positive SeHCAT testing for BAD 1
    • Alternative diagnoses to exclude: microscopic colitis (less likely without nocturnal symptoms), celiac disease, chronic infection
  2. Hepatic steatosis (ICD-10: K76.0 - Fatty liver, not elsewhere classified)

    • Metabolic dysfunction-associated steatotic liver disease (MASLD) given concurrent type 2 diabetes 2
    • Requires fibrosis risk stratification
  3. Type 2 diabetes mellitus, uncontrolled (ICD-10: E11.65 - Type 2 diabetes with hyperglycemia)

    • Glucose 298 mg/dL indicates poor control 2
    • Hepatic steatosis present in 76% of T2DM patients and worsens diabetes outcomes 3
  4. Hypertension (ICD-10: I10 - Essential hypertension)

  5. Nausea and abdominal pain (ICD-10: R11.0 - Nausea; R10.9 - Unspecified abdominal pain)


PLAN

1. Chronic Diarrhea Workup

Immediate Testing:

  • H. pylori urea breath test (CPT: 83013) - as planned, though less likely causative for chronic diarrhea 4
  • Stool studies:
    • Fecal calprotectin (CPT: 83993) to assess for inflammatory diarrhea 5
    • Stool for ova and parasites x3 (CPT: 87177) to exclude Giardia 4
    • Consider fecal elastase if pancreatic insufficiency suspected (not indicated here)

Bile Acid Diarrhea Assessment:

  • Empiric trial of bile acid sequestrant (cholestyramine 4g daily, titrate up) is most practical given 86% pre-test probability in post-cholecystectomy patients 1
  • If SeHCAT testing available (not widely accessible in US): CPT 78299 (unlisted nuclear medicine procedure)
  • Alternative: Serum 7α-hydroxy-4-cholesten-3-one if available 6

GI Referral: For persistent symptoms despite empiric BAD treatment or if alarm features develop

2. Hepatic Steatosis Management

Fibrosis Risk Stratification:

  • Calculate FIB-4 index (age × AST / [platelet count × √ALT]) - first-line noninvasive tool 1
  • Order comprehensive metabolic panel (CPT: 80053) including:
    • AST, ALT, alkaline phosphatase, bilirubin, albumin
    • Assess for hepatic synthetic function
  • CBC with platelets (CPT: 85025) for FIB-4 calculation
  • If FIB-4 suggests intermediate/high risk: Order transient elastography (FibroScan) (CPT: 91200) to quantify fibrosis 1

Additional Labs:

  • Lipid panel (CPT: 80061) - dyslipidemia common with MASLD
  • Hepatitis B and C screening (CPT: 87340,87520) to exclude viral causes

3. Diabetes Management

Immediate Labs:

  • HbA1c (CPT: 83036) to assess long-term control 2
  • Basic metabolic panel (CPT: 80048) - assess renal function given uncontrolled diabetes
  • Urine microalbumin/creatinine ratio (CPT: 82043,82570) - screen for diabetic nephropathy

Medication Optimization:

  • Continue insulin - adjust dose based on home glucose logs and HbA1c 7
  • Resubmit prior authorization for semaglutide (Ozempic):
    • GLP-1 receptor agonists improve both diabetes control AND hepatic steatosis 3
    • Document medical necessity: uncontrolled T2DM (glucose 298 mg/dL) with hepatic steatosis
    • Alternative if denied: consider SGLT-2 inhibitor (dapagliflozin) which also improves hepatic steatosis 3

Diabetes Education:

  • Hypoglycemia recognition and treatment 8
  • Home glucose monitoring - check fasting and 2-hour postprandial
  • Target glucose 80-130 mg/dL fasting, <180 mg/dL postprandial 2

4. Lifestyle Modifications

  • Weight loss goal: >10% body weight through diet and exercise - improves both MASLD and diabetes 6
  • Mediterranean diet - proven effective for hepatic steatosis regression 9
  • Physical activity: 150 minutes/week moderate-intensity exercise 2

5. Follow-Up

  • Return visit in 2-4 weeks (CPT: 99214 - established patient, moderate complexity) to review:
    • Lab results and FIB-4 score
    • Response to bile acid sequestrant
    • Glucose logs and insulin adjustment
    • Insurance authorization status for GLP-1 RA
  • Gastroenterology referral if symptoms persist or FIB-4 indicates significant fibrosis risk
  • Endocrinology referral if diabetes remains uncontrolled despite optimization

CPT CODES FOR TODAY'S VISIT

  • 99214 - Office visit, established patient, 30-39 minutes, moderate complexity medical decision-making

ICD-10 CODES

  1. K91.1 - Postcholecystectomy syndrome (primary)
  2. E11.65 - Type 2 diabetes mellitus with hyperglycemia
  3. K76.0 - Fatty liver, not elsewhere classified
  4. I10 - Essential hypertension
  5. R19.7 - Diarrhea, unspecified
  6. R11.0 - Nausea
  7. R10.9 - Unspecified abdominal pain

Key Clinical Pearls

Post-cholecystectomy diarrhea has 86% likelihood of BAD - empiric bile acid sequestrant trial is reasonable before extensive testing 1. However, do not delay diabetes optimization - glucose of 298 mg/dL significantly increases risk of microvascular complications 2. The combination of hepatic steatosis and uncontrolled diabetes creates a vicious cycle; GLP-1 receptor agonists address both conditions simultaneously and should be aggressively pursued with insurance 3. Calculate FIB-4 immediately to risk-stratify liver disease, as cardiovascular events are the leading cause of death in MASLD patients 10.

Related Questions

What discharge instructions should be given to a patient with hepatic steatosis in a low‑resource setting (e.g., a low‑income country)?
What dietary recommendations are appropriate for managing hepatic steatosis?
Can you help me write a procedure note for an abdominal ultrasound in a 48‑year‑old male with a BMI of 32 kg/m², type 2 diabetes mellitus on metformin, and occasional alcohol use, to evaluate for hepatic steatosis and perform a comprehensive abdominal assessment?
What oral therapy is recommended for a patient with grade 2 hepatic steatosis?
In a middle‑aged adult with compensated metabolic (MASH) cirrhosis (Child‑Pugh A), type 2 diabetes, essential hypertension, primary non‑autoimmune hypothyroidism on levothyroxine 75 µg daily (no liothyronine), and receiving resmetirom 80 mg daily (which suppresses TSH), how should the thyroid medication be titrated effectively?
What are the causes of chronic diarrhea?
What is the recommended management for a patient with leptospirosis who presents with an ST‑segment elevation myocardial infarction (STEMI)?
Is it safe to combine methylphenidate with vortioxetine in a pediatric patient who is also taking pramipexole, considering potential CYP2D6 inhibition and prior intolerance to dexamfetamine?
Can a systemic apoptosis‑inducing drug such as ivermectin cause unintended apoptosis in ocular cells and damage the eyes when used to treat a problem elsewhere in the body?
When is flumazenil indicated for a patient with a benzodiazepine overdose after deliberate self‑harm?
Are there any age‑related contraindications or considerations for using alteplase in older adult patients?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.